Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of LTBI treatment on glucose tolerance and chronic inflammation
2020-001173-69Phase 4Completed
- Sponsor
- Pernille Ravn
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rifampicin and isoniazid in latent tuberculosis infection (LTBI), sponsored by Pernille Ravn. Primary endpoints: Change in glucose tolerance after LTBI eradication and Change in biomarkers of chronic inflammation after LTBI eradication. Started Apr 2020; status: completed.
02
Drugs
rifampicinisoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2020-001173-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001173-69.